Physician profile
Ana Cristina Perez
NPI 1689373615
$4,445.98
in general payments reported to CMS, 2019-2025
14 companies · $2,473 in 2025
The $2,473 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,116 · 2024: $857 · 2025: $2,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,241 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,240.73 |
| Education | $205.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,758.87 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,030.88 | 2023-2025 | Ingrezza |
| Abbvie INC. | $597.95 | 2023-2025 | |
| Alkermes, INC. | $339.40 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $167.67 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.20 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $102.09 | 2023 | Fanapt, Hetlioz |
| Indivior INC. | $71.32 | 2023-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $68.58 | 2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $66.31 | 2023-2024 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $57.11 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $35.67 | 2023 | Auvelity |
| Corium, LLC | $19.34 | 2023 | Azstarys |
| Lundbeck LLC | $18.59 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.